DK2542542T3 - Isotopisk berigede arylsulfonamid-ccr3-antagonister - Google Patents

Isotopisk berigede arylsulfonamid-ccr3-antagonister Download PDF

Info

Publication number
DK2542542T3
DK2542542T3 DK11707755.2T DK11707755T DK2542542T3 DK 2542542 T3 DK2542542 T3 DK 2542542T3 DK 11707755 T DK11707755 T DK 11707755T DK 2542542 T3 DK2542542 T3 DK 2542542T3
Authority
DK
Denmark
Prior art keywords
certain embodiments
deuterium
optionally substituted
substituents
nr1br1c
Prior art date
Application number
DK11707755.2T
Other languages
English (en)
Inventor
Tai Wei Ly
Garrett Thomas Potter
Original Assignee
Axikin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axikin Pharmaceuticals Inc filed Critical Axikin Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2542542T3 publication Critical patent/DK2542542T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

1. Forbindelse med formel I:
eller en enantiomer, en blanding af enantiomerer, en blanding af to eller flere diastereomerer, en tautomer eller en blanding af to eller flere tautomerer deraf; eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf; hvor: R1, R2, R3, R4, R5 og R8 hver for sig er (a) hydrogen, deuterium, halo, cyano, nitro eller guanidin; (b) Ci_6alkyl, C2_ 6alkenyl, C2_6alkynyl, C3-7cycloalkyl, C6-i4aryl, C7_i5aralkyl, heteroaryl eller heterocyclyl; eller (c) -C(0)Rla, -C(0)0Rla, - C (0) NRlbRlc, -C (NRla)NRlbRlc, -0Rla, -0C(0)Rla, -0C(0)0Rla, OC (0) NRlbRlc, -0C (=NRla) NRlbRlc, -0S(0)Rla, -OS (0) 2Rla, OS (0) NRlbRlc, -OS (0) 2NRlbRlc, -NRlbRlc, -NRlaC (0) Rld, -NRlaC (0) 0Rld, -NRlaC (0)NRlbRlc, -NRlaC (=NRld) NRlbRlc, -NRlaS (0) Rld, -NRlaS (0) 2Rld, -NRlaS (0) NRlbRlc, -NRlaS (0) 2NRlbRlc, -SRla, -S(0)Rla, -S (0) 2Rla, S (0) NRlbRlc eller -S (0) 2NRlbRlc; R6, R7 og R9 hver er deuterium; R10 og R11 hver for sig er (a) hydrogen; eller (b) Ci-6alkyl, C2_ 6alkenyl, C2_6alkynyl, C3_7cycloalkyl, C6-i4aryl, C7-isaralkyl, heteroaryl eller heterocyclyl; eller R10 og R11 er koblet sammen til frembringelse af heterocyclyl; R12 er (a) hydrogen; (b) Ci_6alkyl, C2_6alkenyl, C2_6alkynyl, C3-7cycloalkyl, C6-i4aryl, C7-isaralkyl, heteroaryl eller heterocyclyl; eller (c) -C(0)Rla, -C(0)0Rla, -C (0) NRlbRlc, - C (NRla) NRlbRlc, -S(0)Rla, -S(0)2Rla, -S(0)NRlbRlc eller S (0) 2NRlbRlc; L er Ci_6alkylen; X er 0 eller S; og Rla, Rlb, Rlc og Rld hver for sig er hydrogen, deuterium, Ci_ 6alkyl, C2-6alkenyl, C2-6alkynyl, C3_7cycloalkyl, C6-i4aryl, heteroaryl eller heterocyclyl; eller hvert par af Rlb og Rlc sammen med N-atomet, hvortil de er bundet, uafhængigt danner heteroaryl eller heterocyclyl; hvor hver alkyl, alkylen, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl og heteroaryl i R1, R2, R3, R4, R5, R8, R10, R11, R12, Rla, Rlb, Rlc, Rld eller L eventuelt er substitueret med en eller flere substituenter Q, hvor hver Q er udvalgt uafhængigt blandt (a) deuterium, cyano, halo og nitro; (b) Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C3_7cycloalkyl, C6-i4aryl, C7-isaralkyl, heteroaryl og heterocyclyl, som hver eventuelt yderligere er substitueret med en eller flere substituenter Qa; og (c) -C (0) Ra, -C (0) 0Ra, -C(0)NRbRc, -C (NRa) NRbRc, -0Ra, OC (0) Ra, -0C (0) 0Ra, -0C(0)NbR°, -0C (=NRa) NRbR°,-OS (0) Ra, 0S(0)2Ra, -0S(0)NbRc, -OS (0) 2NRbRc, -NRbRc, -NRaC (0) Rd, NRaC (0) 0Rd, -NRaC (0) NRbRc, -NRaC (=NRd) NRbRc, -NRaS (0) Rd, NRaS(0)2Rd, -NRaS (0)NRbRc,-NRaS (0) 2NRbRc, -SRa, -S(0)Ra, -S(0)2Ra, -S(0)NRbRc og -S (0) 2NRbRc, hvor hver Ra, Rb, Rc og Rd uafhængigt er (i) hydrogen eller deuterium; (ii) Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C6-i4aryl, C7-i5aralkyl, heteroaryl eller heterocyclyl, som hver eventuelt er substitueret med en eller flere substituenter Qa; eller (iii) hvert par af Rb og Rc sammen med N-atomet, hvortil de er bundet, danner heterocyclyl, der eventuelt er substitueret med en eller flere substituenter Qa; hvor hver Qa er udvalgt uafhængigt fra gruppen, der består af (a) deuterium, cyano, halo og nitro; (b) Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C6-i4aryl, 07-isaralkyl, heteroaryl og heterocyclyl; og (c) -C(0)Re, -C(0)0Re, -C (0) NRfRg, -C (NRe) NRfRg, -0Re, -0C(0)Re, -OC (0) 0Re, -0C(0)NRfRg, -OC (=NRe) NRfRg, -0S(0)Re, -0S(0)2Re, -OS (0) NRfRg, -OS (0) 2NRfRg, -NRfRg, -NReC (0) Rh, NReC (0) 0Rf, -NReC (0) NRfRg, -NReC (=NRh) NRfRg, -NReS(0)Rh, NReS(0)2Rh, -NReS (0) NRfRg, -NReS (0) 2NRfRg, -SRe, -S(0)Re, -S(0)2Re, -S(0)NRfRg og -S (0) 2NRfRg; hvor hver Re, Rf, Rg og Rb uafhængigt er (i) hydrogen eller deuterium; (ii) Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, C3_7cycloalkyl, C6-i4aryl, C7-i5aralkyl, heteroaryl eller heterocyclyl; eller (iii) hvert par af Rf og Rg sammen med N-atomet, hvortil de er bundet, danner heterocyclyl.
2. Forbindelse ifølge krav 1, der har strukturen med formel II:
eller en enantiomer, en blanding af enantiomerer, en blanding af to eller flere diastereomerer, en tautomer eller en blanding af to eller flere tautomerer deraf; eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf; hvor: R13 er (a) hydrogen, deuterium, halo, cyano, nitro, oxo eller guanidin; (b) Ci_6alkyl, C2_6alkenyl, C2_6alkynyl, C3-7cycloalkyl, C6-i4aryl, C7-i5aralkyl, heteroaryl eller heterocyclyl, som hver eventuelt er substitueret med en eller flere substituenter Q; eller (c) -C (0) Rla,-C (0) 0Rla, -C (0) NRlbRlc, -C (NRla) NRlbRlc, -0Rla, -0C (0) Rla, -0C (0) 0Rla,-0C (0) NRlbRlc, -0C (=NRla) NRlbRlc, -0S(0)Rla, -OS (0) 2Rla, -OS (0) NRlbRlc,-OS (0) 2NRlbRlc, -NRlbRlc, -NRlaC (0) Rld, NRlaC (0) 0Rlcl, -NRlaC (0)NRlbRlc, -NRlaC (=NRlcl) NRlbRlc, -NRlaS (0) Rlcl, -NRlaS (0) 2Rla, -NRlaS (0) NRlbRlc,-NRlaS (0) 2NRlbRlc, -SRla, -S (0) Rla, -S (0) 2Rla, -S(0)NRlbRlc eller -S (0) 2NRlbRlc; hvor Rla, Rlb, Rlc og Rld hver er som defineret heri; m er et helt tal på 0, 1, 2 eller 3; n er et helt tal på 1, 2 eller 3; og p er et helt tal på 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 eller 16.
3. Forbindelse ifølge krav 1 eller 2, hvor R1, R2, R3, R4 og R5 hver for sig er hydrogen, deuterium, halo eller Ci_6alkyl, der eventuelt er substitueret med en eller flere substituenter Q.
4. Forbindelse ifølge krav 3, hvor to af R1, R2, R3, R4 og R5 er halo eller Ci-galkyl, der eventuelt er substitueret med en eller flere substituenter Q; og de resterende tre er hydrogen eller deuterium.
5. Forbindelse ifølge krav 3, hvor to af R1, R2, R3, R4 og R5 er chlor, methyl, -CH2D, -CHD2 eller -CD3; og de resterende tre er hydrogen eller deuterium.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor R2 er chlor, eller hvor R2 er methyl, -CH2D, -CHD2 eller -CD3; og/eller hvor R4 er chlor, eller hvor R4 er methyl, -CH2D, -CHD2 eller -CD3; og/eller hvor R1 er hydrogen, eller hvor R1 er deuterium; og/eller hvor R3 er hydrogen, eller hvor R3 er deuterium; og/eller hvor R5 er hydrogen, eller hvor R5 er deuterium; og/eller hvor R8 er cyano eller nitro, eller hvor R8 er -13CN; og/eller hvor R12 er Ci_6alkyl eller C3_7cycloalkyl, som hver eventuelt er substitueret med en eller flere substituenter Q, eller hvor R12 er -CD3 eller cyclopentyl.
7. Forbindelse ifølge et hvilket som helst af kravene 2 til 6, hvor m er 1; og/eller hvor n er 1 eller 2.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 7, hvor X er 0; eller hvor X er S.
9. Forbindelse ifølge krav 1, hvor forbindelsen er 3 — (4 — cyclopentylpiperazin-l-ylsulfonyl)-4-(3,5-dichlorphenoxy)- 2,5,6-trideuteriumbenzonitril eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 9, hvor forbindelsen er carbon-13-beriget; og/eller hvor mindst ét af atomerne, der er specificeret som isotopisk beriget, har en isotopisk berigelse på mindst ca. 5 %.
11. Forbindelse ifølge et hvilket som helst af kravene 1 til 10, hvor forbindelsen er et hydrochloridsalt.
12. Farmaceutisk præparat, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller en enantiomer, en blanding af enantiomerer, en blanding af to eller flere diastereomerer, en tautomer eller en blanding af to eller flere tautomerer deraf; eller et farmaceutisk acceptabelt salt, solvat eller hydrat deraf; og et eller flere farmaceutisk acceptable bærematerialer eller excipienser; og eventuelt yderligere omfatter et andet terapeutisk middel.
13. Farmaceutisk præparat ifølge krav 12, hvor præparatet er formuleret til enkeltdosisadministration; eventuelt hvor præparatet er formuleret i en oral, parenteral eller intravenøs doseringsform, hvor den orale doseringsform fortrinsvis er en tablet eller en kapsel.
14. Forbindelse ifølge et hvilket som helst af kravene 1 til 11 eller farmaceutisk præparat ifølge krav 12 eller 13 til anvendelse i: en fremgangsmåde til behandling, forebyggelse eller bedring af et eller flere symptomer på en CCR3-medieret forstyrrelse, sygdom eller tilstand; eller en fremgangsmåde til behandling, forebyggelse eller bedring af et eller flere symptomer på en eosinofilforbundet forstyrrelse, sygdom eller tilstand; eller en fremgangsmåde til behandling, forebyggelse eller bedring af et eller flere symptomer på en basofilforbundet forstyrrelse, sygdom eller tilstand; eller en fremgangsmåde til behandling, forebyggelse eller bedring af et eller flere symptomer på en mastcelleforbundet forstyrrelse, sygdom eller tilstand; eller en fremgangsmåde til behandling, forebyggelse eller bedring af et eller flere symptomer på en inflammationssygdom.
15. Forbindelsen eller farmaceutisk præparat til anvendelse ifølge krav 14, hvor forstyrrelsen, sygdommen eller tilstanden er udvalgt fra gruppen, der består af astma, allergisk astma, anstrengelsesastma, allergisk rhinitis, helårsbetinget allergisk rhinitis, sæsonbetinget allergisk rhinitis, atopisk dermatitis, kontaktoverfølsomhed, kontaktdermatitis, konjunktivitis, allergisk konjunktivitis, eosinofil bronkitis, fødevareallergier, eosinofil gastroenteritis, inflammatorisk tarmsygdom, ulcerativ colitis, Crohns sygdom, mastocytose, hyper-IgE-syndrom, systemisk lupus erythematous, psoriasis, akne, multipel sklerose, allograftafstødning, reperfusionsskade, kronisk obstruktiv lungesygdom, Churg-Strauss-syndrom, sinusitis, basofil leukæmi, kronisk urticaria, basofil leukocytosis, psoriasis, eksem, KOL (kronisk obstruktiv lungesygdom), arthritis, rheumatoid arthritis, psoriatisk arthritis, osteoarthritis og kardiovaskulære forstyrrelser; eller hvor forstyrrelsen, sygdommen eller tilstanden er astma, anstrengelsesastma, allergisk rhinitis, atopisk dermatitis, kronisk obstruktiv lungesygdom eller allergisk konjunktivitis.
DK11707755.2T 2010-03-02 2011-03-01 Isotopisk berigede arylsulfonamid-ccr3-antagonister DK2542542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30981510P 2010-03-02 2010-03-02
PCT/US2011/026612 WO2011109345A1 (en) 2010-03-02 2011-03-01 Isotopically enriched arylsulfonamide ccr3 antagonists

Publications (1)

Publication Number Publication Date
DK2542542T3 true DK2542542T3 (da) 2015-07-20

Family

ID=43903983

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11707755.2T DK2542542T3 (da) 2010-03-02 2011-03-01 Isotopisk berigede arylsulfonamid-ccr3-antagonister

Country Status (11)

Country Link
US (1) US8999995B2 (da)
EP (1) EP2542542B1 (da)
AR (1) AR080373A1 (da)
AU (1) AU2011223873B2 (da)
CA (1) CA2791964A1 (da)
DK (1) DK2542542T3 (da)
ES (1) ES2542404T3 (da)
HK (1) HK1180334A1 (da)
HU (1) HUE025699T2 (da)
TW (1) TWI485139B (da)
WO (1) WO2011109345A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298786B (zh) * 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
CN104781240A (zh) * 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
CA2520225C (en) 2003-03-24 2014-08-12 Bayer Healthcare Ag Benzenesulfonamide derivatives
WO2008063600A2 (en) 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
KR101687144B1 (ko) * 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
DK2421829T3 (da) * 2009-04-22 2016-01-04 Axikin Pharmaceuticals Inc 2,5-disubstituerede arylsulfonamid-ccr3-antagonister
EP2502921B1 (en) * 2009-04-22 2015-05-20 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
CN103298786B (zh) * 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂

Also Published As

Publication number Publication date
EP2542542B1 (en) 2015-04-22
US8999995B2 (en) 2015-04-07
US20110218207A1 (en) 2011-09-08
EP2542542A1 (en) 2013-01-09
HUE025699T2 (en) 2016-04-28
AU2011223873A1 (en) 2012-09-20
AU2011223873B2 (en) 2015-06-25
ES2542404T3 (es) 2015-08-05
CA2791964A1 (en) 2011-09-09
AR080373A1 (es) 2012-04-04
TW201136899A (en) 2011-11-01
WO2011109345A1 (en) 2011-09-09
TWI485139B (zh) 2015-05-21
HK1180334A1 (en) 2013-10-18

Similar Documents

Publication Publication Date Title
US8563544B2 (en) 2,5-disubstituted arylsulfonamide CCR3 antagonists
AU2011227232B2 (en) Arylsulfonamide CCR3 antagonists
AU2011313906B2 (en) Salts of arylsulfonamide CCR3 antagonists
DK2502921T3 (da) Arylsulfonamid-CCR3-antagonister
US9637460B2 (en) Isotopically enriched arylsulfonamide CCR3 antagonists
DK2542542T3 (da) Isotopisk berigede arylsulfonamid-ccr3-antagonister